» Articles » PMID: 24465236

Somatic Mutaome Profile in Human Cancer Tissues

Overview
Journal Genomics Inform
Publisher Biomed Central
Specialty Biology
Date 2014 Jan 28
PMID 24465236
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Somatic mutation is a major cause of cancer progression and varied responses of tumors against anticancer agents. Thus, we must obtain and characterize genome-wide mutational profiles in individual cancer subtypes. The Cancer Genome Atlas database includes large amounts of sequencing and omics data generated from diverse human cancer tissues. In the present study, we integrated and analyzed the exome sequencing data from ~3,000 tissue samples and summarized the major mutant genes in each of the diverse cancer subtypes and stages. Mutations were observed in most human genes (~23,000 genes) with low frequency from an analysis of 11 major cancer subtypes. The majority of tissue samples harbored 20-80 different mutant genes, on average. Lung cancer samples showed a greater number of mutations in diverse genes than other cancer subtypes. Only a few genes were mutated with over 5% frequency in tissue samples. Interestingly, mutation frequency was generally similar between non-metastatic and metastastic samples in most cancer subtypes. Among the 12 major mutations, the TP53, USH2A, TTN, and MUC16 genes were found to be frequent in most cancer types, while BRAF, FRG1B, PBRM1, and VHL showed lineage-specific mutation patterns. The present study provides a useful resource to understand the broad spectrum of mutation frequencies in various cancer types.

Citing Articles

Whole-exome sequencing reveals novel genomic signatures and potential therapeutic targets during the progression of rectal neuroendocrine neoplasm.

Xu S, Zhai Z, Zhou P, Xue X, Huang Z, Li X Cell Death Dis. 2024; 15(11):833.

PMID: 39548061 PMC: 11568169. DOI: 10.1038/s41419-024-07232-1.


Identification of a novel histone acetylation-related long non-coding RNA model combined with qRT-PCR experiments for prognosis and therapy in gastric cancer.

Wu Z, Yang X, Yuan Z, Guo Y, Wang X, Qu L Heliyon. 2024; 10(17):e36615.

PMID: 39263162 PMC: 11387370. DOI: 10.1016/j.heliyon.2024.e36615.


A Comprehensive Analysis of HOXB13 Expression in Hepatocellular Carcinoma.

Jeong E, Lee M, Bae A, Kim J, Park J, Lee J Medicina (Kaunas). 2024; 60(5).

PMID: 38792899 PMC: 11123440. DOI: 10.3390/medicina60050716.


Identification of lung adenocarcinoma subtypes and a prognostic signature based on activity changes of the hallmark and immunologic gene sets.

Zhou S, Zeng D, Zhang M, Chen M, Liu Y, Chen Q Heliyon. 2024; 10(7):e28090.

PMID: 38571596 PMC: 10987920. DOI: 10.1016/j.heliyon.2024.e28090.


Preoperative serum CA125 level is a good prognostic predictor in patients with intrahepatic cholangiocarcinoma after hepatectomy: A single-center retrospective study.

Meng J, Weng J, Wu J, Mao H, Huang P, Chen S Medicine (Baltimore). 2023; 102(36):e34839.

PMID: 37682202 PMC: 10489453. DOI: 10.1097/MD.0000000000034839.


References
1.
Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

2.
Greenman C, Stephens P, Smith R, Dalgliesh G, Hunter C, Bignell G . Patterns of somatic mutation in human cancer genomes. Nature. 2007; 446(7132):153-8. PMC: 2712719. DOI: 10.1038/nature05610. View

3.
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

4.
Loeb L, Loeb K, Anderson J . Multiple mutations and cancer. Proc Natl Acad Sci U S A. 2003; 100(3):776-81. PMC: 298677. DOI: 10.1073/pnas.0334858100. View

5.
Greshock J, Bachman K, Degenhardt Y, Jing J, Wen Y, Eastman S . Molecular target class is predictive of in vitro response profile. Cancer Res. 2010; 70(9):3677-86. DOI: 10.1158/0008-5472.CAN-09-3788. View